• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肝硬化无低钠血症及肾功能不全患者腹水的治疗。比较利尿剂与白蛋白补偿穿刺术的随机研究结果]

[Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin].

作者信息

Hagège H, Ink O, Ducreux M, Pelletier G, Buffet C, Etienne J P

机构信息

Service des Maladies du Foie et de l'Appareil Digestif, Centre Hospitalier de Bicêtre, Le Kremlin-Bicêtre.

出版信息

Gastroenterol Clin Biol. 1992;16(10):751-5.

PMID:1478401
Abstract

Previous studies have suggested that treatment of ascites in cirrhotic patients by repeated paracenteses and albumin infusion is fast, effective and safe. In one of these studies including patients with hyponatremia or renal impairment, this treatment was associated with a reduction of duration of hospital stay in comparison with large dose diuretics. The aim of this randomized study was to compare paracentesis with albumin perfusion and low dose diuretics in cirrhotic patients with ascites, but without hyponatremia or renal impairment. Twenty-six patients (group 1) were treated with paracentesis (4 L/day) and 27 patients (group 2) were treated with spironolactone (225 to 300 mg/day), associated with furosemide (40 to 80 mg/day), when inefficient alone. Ascites and peripheric edema disappeared more rapidly in group 1 than in group 2, 8.6 +/- 9.6 vs 13.5 +/- 6.7 days (P = 0.001) and 4.1 +/- 2.6 vs 10.5 +/- 6.5 days (P = 0.001) respectively. During hospitalisation, the incidence of complications was higher in group 2 than in group 1: 56 vs 26% (P = 0.03). Hyponatremia occurred in 30% of patients in group 2 and 4% of patients in group 1 (P = 0.04). The duration of hospital stay was shorter in group 1 (15.0 +/- 10.4 days) than in group 2 (21.0 +/- 11.7 days) (P = 0.007). During follow-up, ascites reappeared in 32% of patients in group 1 and 57% of patients in group 2 (P = 0.09). At 3 months, one patient in group 1 and 2 patients in group 2 developed spontaneous peritonitis whereas survival was similar in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

以往研究表明,通过反复穿刺放腹水及输注白蛋白治疗肝硬化患者的腹水,快速、有效且安全。其中一项纳入低钠血症或肾功能损害患者的研究显示,与大剂量利尿剂相比,该治疗可缩短住院时间。本随机研究旨在比较穿刺放腹水联合白蛋白灌注与小剂量利尿剂治疗无低钠血症或肾功能损害的肝硬化腹水患者的疗效。26例患者(第1组)接受穿刺放腹水治疗(每日4升),27例患者(第2组)接受螺内酯(每日225至300毫克)治疗,单用无效时加用呋塞米(每日40至80毫克)。第1组腹水和外周水肿消失速度比第2组更快,分别为8.6±9.6天对13.5±6.7天(P = 0.001)和4.1±2.6天对10.5±6.5天(P = 0.001)。住院期间,第2组并发症发生率高于第1组:56%对26%(P = 0.03)。第2组30%的患者发生低钠血症,第1组为4%(P = 0.04)。第1组住院时间(15.0±10.4天)短于第2组(21.0±11.7天)(P = 0.007)。随访期间,第1组32%的患者腹水复发,第2组为57%(P = 0.09)。3个月时,第1组1例患者和第2组2例患者发生自发性腹膜炎,两组生存率相似。(摘要截选至250字)

相似文献

1
[Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin].[肝硬化无低钠血症及肾功能不全患者腹水的治疗。比较利尿剂与白蛋白补偿穿刺术的随机研究结果]
Gastroenterol Clin Biol. 1992;16(10):751-5.
2
Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis.肝硬化腹水的治疗。利尿剂、腹腔静脉分流术及大量腹腔穿刺放液术。
Gastroenterol Clin North Am. 1992 Mar;21(1):237-56.
3
[Paracentesis combined with albumin infusion in the treatment of tense ascites in cirrhotic patients].[腹腔穿刺术联合白蛋白输注治疗肝硬化患者的张力性腹水]
Rev Med Chil. 1990 Aug;118(8):874-80.
4
Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study.预防肝硬化腹水穿刺引起的循环功能障碍:标准剂量与半剂量白蛋白。一项前瞻性、随机、非盲的初步研究。
Dig Liver Dis. 2011 Nov;43(11):881-6. doi: 10.1016/j.dld.2011.06.001. Epub 2011 Jul 8.
5
Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites.肝硬化顽固性腹水患者腹腔穿刺放液联合静脉输注白蛋白与腹腔静脉分流术的比较
N Engl J Med. 1991 Sep 19;325(12):829-35. doi: 10.1056/NEJM199109193251201.
6
Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: a randomized prospective study.大量腹腔穿刺放液联合静脉输注白蛋白治疗自发性细菌性腹膜炎患者的长期临床结局:一项随机前瞻性研究
J Gastroenterol Hepatol. 2005 Aug;20(8):1215-22. doi: 10.1111/j.1440-1746.2005.03861.x.
7
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.选择性血管加压素 V2 受体拮抗剂-索他洛尔对肝硬化患者腹水穿刺后腹水复发的影响。
J Hepatol. 2010 Aug;53(2):283-90. doi: 10.1016/j.jhep.2010.02.036. Epub 2010 May 24.
8
Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites.比较白蛋白和生理盐水预防肝硬化腹水患者穿刺放腹水引起的循环功能障碍的随机试验。
Hepatology. 2003 May;37(5):1147-53. doi: 10.1053/jhep.2003.50169.
9
Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.临床试验:高剂量呋塞米联合小容量高渗盐水溶液与反复腹腔穿刺放液治疗难治性腹水的比较。
Aliment Pharmacol Ther. 2009 Aug;30(3):227-35. doi: 10.1111/j.1365-2036.2009.04040.x. Epub 2009 May 12.
10
Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites.
Hepatology. 1991 Apr;13(4):707-13.

引用本文的文献

1
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.失代偿期肝硬化成人腹水的治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD013123. doi: 10.1002/14651858.CD013123.pub2.
2
Efficacy of furosemide for treatment of liver cirrhosis: A systematic review protocol of randomized controlled trial.呋塞米治疗肝硬化的疗效:一项随机对照试验的系统评价方案
Medicine (Baltimore). 2019 Apr;98(16):e15300. doi: 10.1097/MD.0000000000015300.
3
Intravenous albumin infusion is an effective therapy for hyponatremia in patient with malignant ascites.
静脉输注白蛋白是治疗恶性腹水患者低钠血症的有效方法。
Indian J Nephrol. 2014 Jan;24(1):51-3. doi: 10.4103/0971-4065.125116.
4
Hepatic disorders. Features and appropriate management.肝脏疾病。特征及恰当的管理。
Drugs. 1995 Jan;49(1):83-102. doi: 10.2165/00003495-199549010-00007.